Stressor-induced NMDAR dysfunction as a unifying hypothesis for the aetiology, pathogenesis and comorbidity of clinical depression

Medical Hypotheses

Volumn 77, Issue 4, 2011, Pages 508-528

  Marsden, W N ^a  

^a Highclere Court ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM ION; DESIPRAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; FLUOXETINE; GLUCOCORTICOID; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; KETAMINE; LITHIUM; MAGNESIUM ION; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE SYNTHASE; NORADRENALIN; NUCLEAR FACTOR I; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SODIUM ION; THIOREDOXIN; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR NFAT; TRAXOPRODIL; ZINC;

AMYGDALOID NUCLEUS; ANXIETY DISORDER; ARTICLE; ATROPHY; BIOENERGY; BIPOLAR DISORDER; BRAIN BLOOD FLOW; CALCIUM TRANSPORT; CELL ENERGY; CELL PROLIFERATION; COMORBIDITY; DEPRESSION; ENERGY METABOLISM; ENVIRONMENTAL STRESS; ENZYME ACTIVATION; ENZYME ACTIVITY; EXCITOTOXICITY; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GLIA CELL; GLUCOSE UTILIZATION; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNE SYSTEM; INFLAMMATION; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MAGNESIUM DEFICIENCY; MENTAL STRESS; NEGATIVE FEEDBACK; NERVE CELL; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL DEFICIENCY; OXIDATIVE STRESS; PATHOGENESIS; PHOSPHORYLATION AND DEPHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RECEPTOR BINDING; REDOX STRESS; SEROTONIN RELEASE; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS; THERAPY EFFECT;

ANIMALS; DEPRESSION; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; MODELS, THEORETICAL; OXIDATION-REDUCTION; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 80052627971     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.06.021     Document Type: Article

References (362)

1. Ustun T.B. Global burden of depressive disorders in the year 2000. Brit J Psychiat 2004, 184:386-392.
2. Kessler R.C., Nelson C.B., McGonagle K.A., Liu J., Swartz M., Blazer D.G. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Brit J Psychiat 1996, (Suppl.):17-30.
3. Lamers F., van Oppen P., Comijs H.C., Smit J.H., Spinhoven P., van Balkom A.J.L.M., et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiat 2011.
4. Andrade L., Caraveo-Anduaga J.J., Berglund P., Bijl R.V., De Graaf R., Vollebergh W., et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiat Res 2003, 12:3-21.
5. Zöger S., Svedlund J., Holgers K.-M. Relationship between tinnitus severity and psychiatric disorders. Psychosomatics 2006, 47:282-288.
6. Gambassi G. Pain and depression: the egg and the chicken story revisited. Arch Gerontol Geriat 2009, 49(Suppl. 1):103-112.
7. Aben I., Verhey F., Honig A., Lodder J., Lousberg R., Maes M. Research into the specificity of depression after stroke: a review on an unresolved issue. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25:671-689.
8. Breslau N., Lipton R.B., Stewart W.F., Schultz L.R., Welch K.M.A. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology 2003, 60:1308-1312.
9. Wang S.-J., Chen P.-K., Fuh J.-L. Comorbidities of migraine. Frontiers Neurol 2010, 1:16.
10. Seidenberg M., Pulsipher D.T., Hermann B. Association of epilepsy and comorbid conditions. Future Neurol 2009, 4:663-668.
11. Gros D.F., Antony M.M., McCabe R.E., Swinson R.P. Frequency and severity of the symptoms of irritable bowel syndrome across the anxiety disorders and depression. J Anxiety Disorders 2009, 23:290-296.
12. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett 2009, 30:462-469.
13. Yoshiuchi K. Psychological symptoms in chronic fatigue syndrome. Nippon Rinsho, Japan J Clin Med 2007, 65:1023-1027.
14. Modrego P.J. Depression in Alzheimer's disease. Pathophysiology, diagnosis, and treatment. J Alzheimer's Disease: JAD 2010.
15. Caraci F., Copani A., Nicoletti F., Drago F. Depression and Alzheimer' disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 2010, 626:64-71.
16. Storch A., Ebersbach G., Fuchs G., Jost W.H., Odin P., Reifschneider G., et al. Depression in Parkinson's disease. Part 1: epidemiology, signs and symptoms, pathophysiology and diagnosis. Fortschr Neurol Psychiatr 2008, 76:715-724.
17. Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuro-psychopharmacol Biol Psychiat 2011.
18. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J Affect Disord 2010, 125:287-294.
19. Gardner A, Boles RG. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuro-psychopharmacol Biol Psychiat, 2010.
20. Ren X., Dwivedi Y., Mondal A.C., Pandey G.N. Cyclic-AMP response element binding protein (CREB) in the neutrophils of depressed patients. Psychiat Res 2011, 185:108-112.
21. Miller A.L. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev: J Clin Therap 2008, 13:216-226.
22. Nikolaus S., Antke C., Müller H.-W. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behav Brain Res 2009, 204:32-66.
23. Heninger G.R., Delgado P.L., Charney D.S. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996, 29:2-11.
24. Saijo T., Takano A., Suhara T., Arakawa R., Okumura M., Ichimiya T., et al. Effect of electroconvulsive therapy on 5-HT1A receptor binding in patients with depression: a PET study with [11C]WAY 100635. Int J Neuropsychopharmacol/Official Sci J Collegium Int Neuropsychopharmacol (CINP) 2010, 13:785-791.
25. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiat 2010, 15:393-403.
26. Maeng S., Zarate C.A. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiat Rep 2007, 9:467-474.
27. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacol: Official Publ Am College Neuropsychopharmacol 2008, 33:88-109.
28. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiat 2006, 163:28-40.
29. Entsuah A.R., Huang H., Thase M.E. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiat 2001, 62:869-877.
30. Thase M.E., Haight B.R., Richard N., Rockett C.B., Mitton M., Modell J.G., et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiat 2005, 66:974-981.
31. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008, 213:93-118.
32. Rigucci S., Serafini G., Pompili M., Kotzalidis G.D., Tatarelli R. Anatomical and functional correlates in major depressive disorder: the contribution of neuroimaging studies. World J Biol Psychiat: Official J World Federat Soc Biol Psychiat 2010, 11:165-180.
33. Videbech P., Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiat 2004, 161:1957-1966.
34. Kugaya A., Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectrums 2005, 10:808-819.
35. Paul I.A., Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 2003, 1003:250-272.
36. Chatton J.-Y., Pellerin L., Magistretti P.J. GABA uptake into astrocytes is not associated with significant metabolic cost: implications for brain imaging of inhibitory transmission. Proc Natl Acad Sci USA 2003, 100:12456-12461.
37. Caesar K., Hashemi P., Douhou A., Bonvento G., Boutelle M.G., Walls A.B., et al. Glutamate receptor-dependent increments in lactate, glucose and oxygen metabolism evoked in rat cerebellum in vivo. J Physiol 2008, 586:1337-1349.
38. Bak L.K., Schousboe A., Waagepetersen H.S. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem 2006, 98:641-653.
39. Boldyrev A.A., Carpenter D.O., Johnson P. Emerging evidence for a similar role of glutamate receptors in the nervous and immune systems. J Neurochem 2005, 95:913-918.
40. Pellerin L., Magistretti P.J. Ampakine CX546 bolsters energetic response of astrocytes: a novel target for cognitive-enhancing drugs acting as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators. J Neurochem 2005, 92:668-677.
41. Kessels H.W., Malinow R. Synaptic AMPA receptor plasticity and behavior. Neuron 2009, 61:340-350.
42. Paoletti P., Neyton J. NMDA receptor subunits: function and pharmacology Molecular organization and operation of NMDARs. Curr Opin Pharmacol 2007.
43. Wolosker H. d-Serine regulation of NMDA receptor activity. Sci STKE: Signal Transduct Knowl Environ 2006;2006:pe41.
44. Zhang H.X., Hyrc K., Thio L.L. The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine. J Physiol 2009, 587:3207-3220.
45. Rebola N., Srikumar B.N., Mulle C. Activity-dependent synaptic plasticity of NMDA receptors. J Physiol 2010, 588:93-99.
46. Yashiro K., Philpot B.D. Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology 2008, 55:1081-1094.
47. Cooke S.F., Bliss T.V.P. Plasticity in the human central nervous system. Brain: J Neurol 2006, 129:1659-1673.
48. Whitlock J.R., Heynen A.J., Shuler M.G., Bear M.F. Learning induces long-term potentiation in the hippocampus. Science 2006, 313:1093-1097.
49. Li G.H., Jackson M.F., Orser B.A., MacDonald J.F. Reciprocal and activity-dependent regulation of surface AMPA and NMDA receptors in cultured neurons. Int J Physiol Pathophysiol Pharmacol 2010.
50. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010, 11:682-696.
51. Soriano F.X., Papadia S., Hofmann F., Hardingham N.R., Bading H., Hardingham G.E. Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J Neurosci: Official J Soc Neurosci 2006, 26:4509-4518.
52. Haydon P.G., Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev 2006, 86:1009-1031.
53. Benz B., Grima G., Do K.Q. Glutamate-induced homocysteic acid release from astrocytes: possible implication in glia-neuron signaling. Neuroscience 2004, 124:377-386.
54. Petralia R.S., Wang Y.X., Hua F., Yi Z., Zhou A., Ge L. Et al., Organization of NMDA receptors at extrasynaptic locations. Neuroscience 2010, 167:68-87.
55. Carmignoto G., Fellin T. Glutamate release from astrocytes as a non-synaptic mechanism for neuronal synchronization in the hippocampus. J Physiol 2006, 99:98-102.
56. Rusakov D.A., Kullmann D.M. Extrasynaptic glutamate diffusion in the hippocampus: ultrastructural constraints, uptake, and receptor activation. J Neurosci: Official J Soc Neurosci 1998, 18:3158-3170.
57. Zhao J.-P., Constantine-Paton M. NR2A-/- mice lack long-term potentiation but retain NMDA receptor and L-type Ca2+ channel-dependent long-term depression in the juvenile superior colliculus. J Neurosci: Official J Soc Neurosci 2007, 27:13649-13654.
58. Zheng S., Eacker S.M., Hong S.J., Gronostajski R.M., Dawson T.M., Dawson V.L. NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. J Clin Investig 2010, 120:2446-2456.
59. Nordquist N., Oreland L. Serotonin, genetic variability, behaviour, and psychiatric disorders - a review. Ups J Med Sci 2010, 115:2-10.
60. Drevets W.C., Thase M.E., Moses-Kolko E.L., Price J., Frank E., Kupfer D.J., et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol 2007, 34:865-877.
61. Shelton R.C., Sanders-Bush E., Manier D.H., Lewis D.A. Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 2009, 158:1406-1415.
62. Pandey G.N., Dwivedi Y., Pandey S.C., Conley R.R., Roberts R.C., Tamminga C.A. Protein kinase C in the postmortem brain of teenage suicide victims. Neurosci Lett 1997, 228:111-114.
63. Cannon D.M., Klaver J.M., Peck S.A., Rallis-Voak D., Erickson K., Drevets W.C. Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112. Neuropsychopharmacol: Official Publication Am College Neuropsychopharmacol 2009, 34:1277-1287.
64. Nikolaus S., Antke C., Beu M., Müller H.-W. Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders - results from in vivo imaging studies. Rev Neurosci 2010, 21:119-139.
65. Hesse S., Müller U., Lincke T., Barthel H., Villmann T., Angermeyer M.C., et al. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiat Res 2005, 140:63-72.
66. Richardson-Jones J.W., Craige C.P., Guiard B.P., Stephen A., Metzger K.L., Kung H.F., et al. 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 2010, 65:40-52.
67. Starr K.R., Price G.W., Watson J.M., Atkinson P.J., Arban R., Melotto S., et al. SB-649,915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test. Neuropsychopharmacol: Official Publication Am College Neuropsychopharmacol 2007, 32:2163-2172.
68. Kloda A., Adams D.J. Mutations within the selectivity filter of the NMDA receptor-channel influence voltage dependent block by 5-hydroxytryptamine. Br J Pharmacol 2006, 149:163-169.
69. Kloda A., Adams D.J. Voltage-dependent inhibition of recombinant NMDA receptor-mediated currents by 5-hydroxytryptamine. Br J Pharmacol 2005, 144:323-330.
70. Pittaluga A., Raiteri L., Longordo F., Luccini E., Barbiero V.S., Racagni G. Et al., Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. Neuropharmacology 2007, 53:27-36.
71. Bonanno G., Giambelli R., Raiteri L., Tiraboschi E., Zappettini S., Musazzi L., et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci: Official J Soc Neurosci 2005, 25:3270-3279.
72. Szasz B.K., Mike A., Karoly R., Gerevich Z., Illes P., Vizi E.S., et al. Direct inhibitory effect of fluoxetine on N-methyl-D-aspartate receptors in the central nervous system. Biol Psychiat 2007, 62:1303-1309.
73. Mayer A., Szasz B.K., Kiss J.P. Inhibitory effect of antidepressants on the NMDA-evoked [(3)H]noradrenaline release from rat hippocampal slices. Neurochem Int 2009, 55:383-388.
74. Yuen E.Y., Jiang Q., Chen P., Feng J., Yan Z. Activation of 5-HT2A/C receptors counteracts 5-HT1A regulation of n-methyl-D-aspartate receptor channels in pyramidal neurons of prefrontal cortex. J Biol Chem 2008, 283:17194-17204.
75. Yuen E.Y., Jiang Q., Chen P., Gu Z., Feng J., Yan Z. Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism. J Neurosci: Official J Soc Neurosci 2005, 25:5488-5501.
76. Martínez-Turrillas R., Del Río J., Frechilla D. Neuronal proteins involved in synaptic targeting of AMPA receptors in rat hippocampus by antidepressant drugs. Biochem Biophys Res Commun 2007, 353:750-755.
77. Svenningsson P., Tzavara E.T., Witkin J.M., Fienberg A.A., Nomikos G.G., Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci USA 2002, 99:3182-3187.
78. Madhavan L., Freed W.J., Anantharam V., Kanthasamy A.G. 5-hydroxytryptamine 1A receptor activation protects against N-methyl-D-aspartate-induced apoptotic cell death in striatal and mesencephalic cultures. J Pharmacol Exp Therap 2003, 304:913-923.
79. Kamei J., Igarashi H., Kasuya Y. Modulation by serotonin of glutamate-induced lethality in mice. Res Commun Chem Pathol Pharmacol 1991, 74:167-184.
80. Stutzmann G.E., LeDoux J.E. GABAergic antagonists block the inhibitory effects of serotonin in the lateral amygdala: a mechanism for modulation of sensory inputs related to fear conditioning. J Neurosci: Official J Soc Neurosci 1999, 19:RC8.
81. Bhagwagar Z. Increased Brain GABA Concentrations Following Acute Administration of a Selective Serotonin Reuptake Inhibitor. Am J Psychiat 2004, 161:368-370.
82. Pinna G., Costa E., Guidotti A. SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr Opin Pharmacol 2009, 9:24-30.
83. Yüksel C., Ongür D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiat 2010, 68:785-794.
84. Horn D.I., Yu C., Steiner J., Buchmann J., Kaufmann J., Osoba A., et al. Glutamatergic and resting state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insula. Frontiers Syst Neurosci 2010, 4.
85. Feyissa A.M., Chandran A., Stockmeier C.A., Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiat 2009, 33:70-75.
86. Karolewicz B., Szebeni K., Gilmore T., Maciag D., Stockmeier C.A., Ordway G.A. Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. Int J Neuropsychopharmacol/Official Sci J Collegium Int Neuropsychopharmacol (CINP) 2009, 12:143-153.
87. Karolewicz B., Stockmeier C.A., Ordway G.A. Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression. Neuropsychopharmacol: Official Publication Am College Neuropsychopharmacol 2005, 30:1557-1567.
88. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., Meador-Woodruff J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacol: Official Publication Am College Neuropsychopharmacol 2007, 32:1888-1902.
89. Beneyto M., Meador-Woodruff J.H. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacol: Official Publication Am College Neuropsychopharmacol 2008, 33:2175-2186.
90. Diazgranados N., Ibrahim L.A., Brutsche N.E., Ameli R., Henter I.D., Luckenbaugh D.A., et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiat 2010, 71:1605-1611.
91. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiat 2010, 67:793-802.
92. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiat 2000, 47:351-354.
93. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiat 2006, 63:856-864.
94. Li N., Lee B., Liu R.-J., Banasr M., Dwyer J.M., Iwata M. Et al., mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
95. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiat 2008, 63:349-352.
96. Machado-Vieira R., Yuan P., Brutsche N., DiazGranados N., Luckenbaugh D., Manji H.K., et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-d-aspartate antagonist. J Clin Psychiat 2009, 70:1662-1666.
97. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008, 28:631-637.
98. Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol n.d.;30:136-44.
99. Muhonen L.H., Lönnqvist J., Juva K., Alho H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiat 2008, 69:392-399.
100. Réus G.Z., Stringari R.B., Kirsch T.R., Fries G.R., Kapczinski F., Roesler R., et al. Neurochemical and behavioural effects of acute and chronic memantine administration in rats: further support for NMDA as a new pharmacological target for the treatment of depression?. Brain Res Bull 2010, 81:585-589.
101. Szewczyk B., Poleszak E., Sowa-Kućma M., Wróbel A., Słotwiński S., Listos J., et al. The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids 2009, 39:205-217.
102. Gould T.D., O'Donnell K.C., Dow E.R., Du J., Chen G., Manji H.K. Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology 2008, 54:577-587.
103. Dhir A., Kulkarni S.K. Possible involvement of nitric oxide (NO) signaling pathway in the antidepressant-like effect of MK-801(dizocilpine), a NMDA receptor antagonist in mouse forced swim test. Indian J Exp Biol 2008, 46:164-170.
104. Karasawa J.-I., Shimazaki T., Kawashima N., Chaki S. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 2005, 1042:92-98.
105. Fumagalli F., Pasini M., Sartorius A., Scherer R., Racagni G., Riva M.A., et al. Repeated electroconvulsive shock (ECS) alters the phosphorylation of glutamate receptor subunits in the rat hippocampus. Int J Neuropsychopharmacol/Official Sci J Collegium Int Neuropsychopharmacol (CINP) 2010, 13:1255-1260.
106. Dybała M., Siwek A., Poleszak E., Pilc A., Nowak G. Lack of NMDA-AMPA interaction in antidepressant-like effect of CGP 37849, an antagonist of NMDA receptor, in the forced swim test. J Neural Transmission (Vienna, Austria: 1996) 2008, 115:1519-1520.
107. O'Neill M.J., Bleakman D., Zimmerman D.M., Nisenbaum E.S. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets: CNS Neurol Disord 2004, 3:181-194.
108. Bleakman D., Alt A., Witkin J.M. AMPA receptors in the therapeutic management of depression. CNS Neurol Disord: Drug Targets 2007, 6:117-126.
109. Amico F., Meisenzahl E., Koutsouleris N., Reiser M., Möller H.-J., Frodl T. Structural MRI correlates for vulnerability and resilience to major depressive disorder. J Psychiat Neurosci: JPN 2010.
110. Dotson V.M., Davatzikos C., Kraut M.A., Resnick S.M. Depressive symptoms and brain volumes in older adults: a longitudinal magnetic resonance imaging study. J Psychiat Neurosci, JPN 2009, 34:367-375.
111. Felmingham K., Williams L.M., Whitford T.J., Falconer E., Kemp A.H., Peduto A., et al. Duration of posttraumatic stress disorder predicts hippocampal grey matter loss. NeuroReport 2009, 20:1402-1406.
112. Schmidt H.D., Banasr M., Duman R.S. Future antidepressant targets: neurotrophic factors and related signaling cascades. Drug Discov Today. Therapeut Strategies 2008, 5:151-156.
113. Okamoto H., Voleti B., Banasr M., Sarhan M., Duric V., Girgenti M.J., et al. Wnt2 expression and signaling is increased by different classes of antidepressant treatments. Biol Psychiat 2010, 68:521-527.
114. Gourley S.L., Wu F.J., Kiraly D.D., Ploski J.E., Kedves A.T., Duman R.S., et al. Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol Psychiat 2008, 63:353-359.
115. Réus G.Z., Stringari R.B., Ribeiro K.F., Ferraro A.K., Vitto M.F., Cesconetto P., et al. Ketamine plus imipramine treatment induces antidepressant-like behavior and increases creb and bdnf protein levels and pka and pkc phosphorilation in rat brain. Behav Brain Res 2011.
116. Li X., Zhu W., Roh M.-S., Friedman A.B., Rosborough K., Jope R.S. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacol: Official Publication Am College Neuropsychopharmacol 2004, 29:1426-1431.
117. Boldrini M., Underwood M.D., Hen R., Rosoklija G.B., Dwork A.J., John Mann J., et al. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacol: Official Publication Am College Neuropsychopharmacol 2009, 34:2376-2389.
118. Schmidt H.D., Duman R.S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 2007, 18:391-418.
119. Deltheil T., Guiard B.P., Cerdan J., David D.J., Tanaka K.F., Repérant C., et al. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology 2008, 55:1006-1014.
120. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
121. Chen F., Madsen T.M., Wegener G., Nyengaard J.R. Repeated electroconvulsive seizures increase the total number of synapses in adult male rat hippocampus. Eur Neuropsychopharmacol: J Eur College Neuropsychopharmacol 2009, 19:329-338.
122. Aydemir O., Deveci A. BDNF measurement in stress-related mood disorders: a review of clinical studies. Türk Psikiyatri Dergisi=Turkish J Psychiat 2009, 20:385-391.
123. Deltheil T., Tanaka K., Reperant C., Hen R., David D.J., Gardier A.M. Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice. Int J Neuropsychopharmacol/Official Sci J Collegium Int Neuropsychopharmacol (CINP) 2009, 1-11.
124. Kumar A., Garg R., Gaur V., Kumar P. Venlafaxine involves nitric oxide modulatory mechanism in experimental model of chronic behavior despair in mice. Brain Res 2010, 1311:73-80.
125. Krass M., Wegener G., Vasar E., Volke V. The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behav Brain Res 2010.
126. Ulak G., Mutlu O., Akar F.Y., Komsuoĝlu F.I., Tanyeri P., Erden B.F. Neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole augment the effects of antidepressants acting via serotonergic system in the forced swimming test in rats. Pharmacol Biochem Behav 2008, 90:563-568.
127. Crespi F. The selective serotonin reuptake inhibitor fluoxetine reduces striatal in vivo levels of voltammetric nitric oxide (NO): a feature of its antidepressant activity?. Neurosci Lett 2010, 470:95-99.
128. Zhang J., Huang X.-Y., Ye M.-L., Luo C.-X., Wu H.-Y., Hu Y., et al. Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A receptor in modulating anxiety-related behaviors. J Neurosci: Official J Soc Neurosci 2010, 30:2433-2441.
129. Gałecki P., Maes M., Florkowski A., Lewiński A., Gałecka E., Bieńkiewicz M., et al. An inducible nitric oxide synthase polymorphism is associated with the risk of recurrent depressive disorder. Neurosci Lett 2010, 486:184-187.
130. Oliveira RMW, Guimarães FS, Deakin JFW. Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res=Revista Brasileira De Pesquisas Médicas E Biológicas/Sociedade Brasileira De Biofísica ... [et Al.] 2008;41:333.
131. Oh D.H., Park Y.C., Kim S.H. Increased glycogen synthase kinase-3β mRNA level in the hippocampus of patients with major depression: a study using the Stanley neuropathology consortium integrative database. Psychiat Investig 2010, 7:202-207.
132. Li N., Liu R.-J., Dwyer J.M., Banasr M., Lee B., Son H., et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiat 2011.
133. Lachamp P.M., Liu Y., Liu S.J. Glutamatergic modulation of cerebellar interneuron activity is mediated by an enhancement of GABA release and requires protein kinase A/RIM1alpha signaling. J Neurosci: Official J Soc Neurosci 2009, 29:381-392.
134. Miwa H., Fukaya M., Watabe A.M., Watanabe M., Manabe T. Functional contributions of synaptically localized NR2B subunits of the NMDA receptor to synaptic transmission and long-term potentiation in the adult mouse CNS. J Physiol 2008, 586:2539-2550.
135. Caudal D., Godsil B.P., Mailliet F., Bergerot D., Jay T.M. Acute stress induces contrasting changes in ampa receptor subunit phosphorylation within the prefrontal cortex, amygdala and hippocampus. PloS One 2010, 5:e15282.
136. Pozo K., Goda Y. Unraveling mechanisms of homeostatic synaptic plasticity. Neuron 2010, 66:337-351.
137. Smart ICDATG. Presynaptic NMDA Receptors - Biology of the NMDA Receptor - NCBI Bookshelf, 2009.
138. Corlew R., Brasier D.J., Feldman D.E., Philpot B.D. Presynaptic NMDA receptors: newly appreciated roles in cortical synaptic function and plasticity. Neurosci: Rev J Bring Neurobiol, Neurol Psychiat 2008, 14:609-625.
139. Marek G.J., Behl B., Bespalov A.Y., Gross G., Lee Y., Schoemaker H. Glutamatergic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?. Mol Pharmacol 2010, 77:317-326.
140. Xi D., Keeler B., Zhang W., Houle J.D., Gao W.-J. NMDA receptor subunit expression in GABAergic interneurons in the prefrontal cortex: application of laser microdissection technique. J Neurosci Methods 2009, 176:172-181.
141. Rajkowska G., Miguel-Hidalgo J.J. Gliogenesis and glial pathology in depression. CNS Neurol Disord: Drug Targets 2007, 6:219-233.
142. Postnov D.E., Koreshkov R.N., Brazhe N.A., Brazhe A.R., Sosnovtseva O.V. Dynamical patterns of calcium signaling in a functional model of neuron-astrocyte networks. J Biol Phys 2009, 35:425-445.
143. Lalo U., Pankratov Y., Kirchhoff F., North R.A., Verkhratsky A. NMDA receptors mediate neuron-to-glia signaling in mouse cortical astrocytes. J Neurosci: Official J Soc Neurosci 2006, 26:2673-2683.
144. Lee M.-C., Ting K.K., Adams S., Brew B.J., Chung R., Guillemin G.J. Characterisation of the expression of NMDA receptors in human astrocytes. PloS One 2010, 5:e14123.
145. Káradóttir R., Cavelier P., Bergersen L.H., Attwell D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005, 438:1162-1166.
146. Micu I., Jiang Q., Coderre E., Ridsdale A., Zhang L., Woulfe J., et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 2006, 439:988-992.
147. Tham M.W., Woon P.S., Sum M.Y., Lee T.-S., Sim K. White matter abnormalities in major depression: Evidence from post-mortem, neuroimaging and genetic studies. Journal Of affective Disorders 2010.
148. Shelton R.C., Hal Manier D., Lewis D.A. Protein kinases A and C in post-mortem prefrontal cortex from persons with major depression and normal controls. Int J Neuropsychopharmacol/Official Sci J Collegium Int Neuropsychopharmacol (CINP) 2009, 12:1223-1232.
149. Dwivedi Y., Rao J.S., Rizavi H.S., Kotowski J., Conley R.R., Roberts R.C., et al. Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003, 60:273-282.
150. Dwivedi Y., Rizavi H.S., Roberts R.C., Conley R.C., Tamminga C.A., Pandey G.N. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem 2001, 77:916-928.
151. Duric V., Banasr M., Licznerski P., Schmidt H.D., Stockmeier C.A., Simen A.A., et al. A negative regulator of MAP kinase causes depressive behavior. Nat Med 2010, 16:1328-1332.
152. Dwivedi Y., Rizavi H.S., Zhang H., Roberts R.C., Conley R.R., Pandey G.N. Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain role of ERK kinase 1 (MEK1). Int J Neuropsychopharmacol/Official Sci J Collegium Int Neuropsychopharmacol (CINP) 2009, 12:1337-1354.
153. Karege F., Perroud N., Burkhardt S., Schwald M., Ballmann E., La Harpe R., et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiat 2007, 61:240-245.
154. Polter A., Yang S., Zmijewska A.A., Van Groen T., Paik J.-H., Depinho R.A., et al. Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation. Biol Psychiat 2009, 65:150-159.
155. Lu W., Man H., Ju W., Trimble W.S., MacDonald J.F., Wang Y.T. Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron 2001, 29:243-254.
156. Xia P., Chen H.-s V., Zhang D., Lipton S.A. Memantine Preferentially Blocks Extrasynaptic over Synaptic NMDA Receptor Currents in Hippocampal Autapses. J Neurosci 2010, 30:11246-11250.
157. Schmidt M.V., Trümbach D., Weber P., Wagner K., Scharf S.H., Liebl C., et al. Individual stress vulnerability is predicted by short-term memory and AMPA receptor subunit ratio in the hippocampus. J Neurosci: Official J Soc Neurosci 2010, 30:16949-16958.
158. Baune B.T., Miller R., McAfoose J., Johnson M., Quirk F., Mitchell D. The role of cognitive impairment in general functioning in major depression. Psychiat Res 2010, 176:183-189.
159. Nissen C., Holz J., Blechert J., Feige B., Riemann D., Voderholzer U., et al. Learning as a model for neural plasticity in major depression. Biol Psychiat 2010, 68:544-552.
160. Massey P.V., Johnson B.E., Moult P.R., Auberson Y.P., Brown M.W., Molnar E., et al. Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. J Neurosci: Official J Soc Neurosci 2004, 24:7821-7828.
161. Yang C.-H., Huang C.-C., Hsu K.-S. Behavioral stress enhances hippocampal CA1 long-term depression through the blockade of the glutamate uptake. J Neurosci: Official J Soc Neurosci 2005, 25:4288-4293.
162. Danysz W., Parsons C.G., Mobius H.J., Stoffler A., Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease-a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Res 2000, 2:85-97.
163. Izumi Y., Tokuda K., Zorumski C.F. Long-term potentiation inhibition by low-level N-methyl-D-aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen-activated protein kinase. Hippocampus 2008, 18:258-265.
164. Xu J., Kurup P., Zhang Y., Goebel-Goody S.M., Wu P.H., Hawasli A.H., et al. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J Neurosci: Official J Soc Neurosci 2009, 29:9330-9343.
165. Wang X.-B., Yang Y., Zhou Q. Independent expression of synaptic and morphological plasticity associated with long-term depression. J Neurosci: Official J Soc Neurosci 2007, 27:12419-12429.
166. Christian K.M., Miracle A.D., Wellman C.L., Nakazawa K. Chronic stress-induced hippocampal dendritic retraction requires CA3 NMDA receptors. Neuroscience 2011, 174:26-36.
167. Stockmeier C.A., Mahajan G.J., Konick L.C., Overholser J.C., Jurjus G.J., Meltzer H.Y., et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiat 2004, 56:640-650.
168. Abraham W.C., Bear M.F. Metaplasticity: the plasticity of synaptic plasticity. Trends Neurosci 1996, 19:126-130.
169. Siegle G.J., Thompson W., Carter C.S., Steinhauer S.R., Thase M.E. Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiat 2007, 61:198-209.
170. Gao C., Gill M.B., Tronson N.C., Guedea A.L., Guzmán Y.F., Huh K.H., et al. Hippocampal NMDA receptor subunits differentially regulate fear memory formation and neuronal signal propagation. Hippocampus 2010, 20:1072-1082.
171. Law A.J., Deakin J.F. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. NeuroReport 2001, 12:2971-2974.
172. Drevets W.C. Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci 1999, 877:614-637.
173. Hamilton J.P., Siemer M., Gotlib I.H. Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Mol Psychiat 2008, 13:993-1000.
174. Hamidi M., Drevets W.C., Price J.L. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiat 2004, 55:563-569.
175. Tsvetkov E., Shin R.M., Bolshakov V.Y. Glutamate uptake determines pathway specificity of long-term potentiation in the neural circuitry of fear conditioning. Neuron 2004, 41:139-151.
176. Sun L., June Liu S. Activation of extrasynaptic NMDA receptors induces a PKC-dependent switch in AMPA receptor subtypes in mouse cerebellar stellate cells. J Physiol 2007, 583:537-553.
177. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci: Official J Soc Neurosci 1997, 17:2921-2927.
178. Lakhan S.E., Callaway E. Deep brain stimulation for obsessive-compulsive disorder and treatment-resistant depression: systematic review. BMC Res Notes 2010, 3:60.
179. Karasawa J.-I., Kotani M., Kambe D., Chaki S. AMPA receptor mediates mGlu 2/3 receptor antagonist-induced dopamine release in the rat nucleus accumbens shell. Neurochem Int 2010, 57:615-619.
180. Del Arco A., Segovia G., Mora F. Blockade of NMDA receptors in the prefrontal cortex increases dopamine and acetylcholine release in the nucleus accumbens and motor activity. Psychopharmacology 2008, 201:325-338.
181. Chen B.T., Hopf F.W., Bonci A. Synaptic plasticity in the mesolimbic system: therapeutic implications for substance abuse. Ann N Y Acad Sci 2010, 1187:129-139.
182. Chourbaji S., Vogt M.A., Fumagalli F., Sohr R., Frasca A., Brandwein C., et al. AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. FASEB J: Official Publication Federat Am Soc Exp Biol 2008, 22:3129-3134.
183. Terunuma M., Vargas K.J., Wilkins M.E., Ramírez O.A., Jaureguiberry-Bravo M., Pangalos M.N., et al. Prolonged activation of NMDA receptors promotes dephosphorylation and alters postendocytic sorting of GABAB receptors. Proc Natl Acad Sci USA 2010, 107:13918-13923.
184. Trajkovska V., Santini M.A., Marcussen A.B., Thomsen M.S., Hansen H.H., Mikkelsen J.D., et al. BDNF downregulates 5-HT(2A) receptor protein levels in hippocampal cultures. Neurochem Int 2009, 55:697-702.
185. Casarotto P.C., de Bortoli V.C., Corrêa F.M.deA., Resstel L.B.M., Zangrossi H. Panicolytic-like effect of BDNF in the rat dorsal periaqueductal grey matter: the role of 5-HT and GABA. Int J Neuropsychopharmacol/Official Sci J Collegium Int Neuropsychopharmacol (CINP) 2010, 13:573-582.
186. Pu S., Yamada T., Yokoyama K., Matsumura H., Kobayashi H., Sasaki N., et al. A multi-channel near-infrared spectroscopy study of prefrontal cortex activation during working memory task in major depressive disorder. Neurosci Res 2011.
187. Magistretti P.J. Neuron-glia metabolic coupling and plasticity. J Exp Biol 2006, 209:2304-2311.
188. Renshaw P.F., Parow A.M., Hirashima F., Ke Y., Moore C.M., Frederick B.De B., et al. Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. Am J Psychiat 2001, 158:2048-2055.
189. Iosifescu D.V., Bolo N.R., Nierenberg A.A., Jensen J.E., Fava M., Renshaw P.F. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiat 2008, 63:1127-1134.
190. Scaini G., Santos P.M., Benedet J., Rochi N., Gomes L.M., Borges L.S., et al. Evaluation of Krebs cycle enzymes in the brain of rats after chronic administration of antidepressants. Brain Res Bull 2010, 82:224-227.
191. Nicholls D.G. Oxidative stress and energy crises in neuronal dysfunction. Ann N Y Acad Sci 2008, 1147:53-60.
192. Gallagher C.N., Carpenter K.L.H., Grice P., Howe D.J., Mason A., Timofeev I., et al. The human brain utilizes lactate via the tricarboxylic acid cycle: a 13C-labelled microdialysis and high-resolution nuclear magnetic resonance study. Brain: J Neurol 2009, 132:2839-2849.
193. Kasischke K.A., Vishwasrao H.D., Fisher P.J., Zipfel W.R., Webb W.W. Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis. Science 2004, 305:99-103.
194. Bolaños J.P., Almeida A., Moncada S. Glycolysis: a bioenergetic or a survival pathway?. Trends Biochem Sci 2010, 35:145-149.
195. Bittner C.X., Loaiza A., Ruminot I., Larenas V., Sotelo-Hitschfeld T., Gutiérrez R., et al. High resolution measurement of the glycolytic rate. Frontiers Neuroenerget 2010, 2.
196. Che Y., Wang J.-F., Shao L., Young T. Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. J Psychiat Neurosci, JPN 2010, 35:296-302.
197. Gawryluk J.W., Wang J.-F., Andreazza A.C., Shao L., Young L.T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol/Official Sci J Collegium Int Neuropsychopharmacol (CINP) 2010, 14:1-8.
198. Qu K., Lee S.W., Bian J.S., Low C.-M., Wong P.T.-H. Hydrogen sulfide: neurochemistry and neurobiology. Neurochem Int 2008, 52:155-165.
199. Kimura Y., Goto Y.-I., Kimura H. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid Redox Signaling 2010, 12:1-13.
200. Kimura Y., Dargusch R., Schubert D., Kimura H. Hydrogen sulfide protects HT22 neuronal cells from oxidative stress. Antioxid Redox Signaling 2006, 8:661-670.
201. Liu H.-T., Hollmann M.W., Liu W.-H., Hoenemann C.W., Durieux M.E. Modulation of NMDA Receptor Function by Ketamine and Magnesium: Part I. Anesth Analg 2001, 92:1173-1181.
202. Ongür D., Jensen J.E., Prescot A.P., Stork C., Lundy M., Cohen B.M., et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiat 2008, 64:718-726.
203. Du J., Gray N.A., Falke C.A., Chen W., Yuan P., Szabo S.T., et al. Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci: Official J Soc Neurosci 2004, 24:6578-6589.
204. Watt A.J., van Rossum M.C., MacLeod K.M., Nelson S.B., Turrigiano G.G. Activity coregulates quantal AMPA and NMDA currents at neocortical synapses. Neuron 2000, 26:659-670.
205. Bazhenov A.V., Kleshchevnikov A.M. Reciprocal inhibition of the AMPA and NMDA components of excitatory postsynaptic potentials in field CA1 of the rat hippocampus in vitro. Neurosci Behav Physiol 1999, 29:719-725.
206. Lu W., Gray J.A., Granger A.J., During M.J., Nicoll R.A. The potentiation of synaptic AMPA receptors induced by the deletion of NMDA receptors requires the GluA2 subunit. J Neurophysiol 2010.
207. Shen G., Tietz E.I. Down-regulation of synaptic GluN2B subunit-containing N-methyl-d-aspartate receptors: a physiological brake on CA1 neuron {alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid hyperexcitability during benzodiazepine withdrawal. J Pharmacol Exp Therapeut 2011, 336:265-273.
208. Bao A.-M., Swaab D.F. Corticotropin-releasing hormone and arginine vasopressin in depression focus on the human postmortem hypothalamus. Vitam Horm 2010, 82:339-365.
209. Lucassen P.J., Meerlo P., Naylor A.S., van Dam A.M., Dayer A.G., Fuchs E., et al. Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: implications for depression and antidepressant action. Eur Neuropsychopharmacol: J Eur College Neuropsychopharmacol 2010, 20:1-17.
210. Koo J.W., Russo S.J., Ferguson D., Nestler E.J., Duman R.S. Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci USA 2010, 107:2669-2674.
211. Shansky R.M., Morrison J.H. Stress-induced dendritic remodeling in the medial prefrontal cortex: effects of circuit, hormones and rest. Brain Res 2009, 1293:108-113.
212. Coussens C.M., Kerr D.S., Abraham W.C. Glucocorticoid receptor activation lowers the threshold for NMDA-receptor-dependent homosynaptic long-term depression in the hippocampus through activation of voltage-dependent calcium channels. J Neurophysiol 1997, 78:1-9.
213. Leza J.C., Salas E., Sawicki G., Russell J.C., Radomski M.W. The effects of stress on homeostasis in JCR-LA-cp rats: the role of nitric oxide. J Pharmacol Exp Therapeut 1998, 286:1397-1403.
214. Jauregui-Huerta F., Ruvalcaba-Delgadillo Y., Gonzalez-Castañeda R., Garcia-Estrada J., Gonzalez-Perez O., Luquin S. Responses of glial cells to stress and glucocorticoids. Curr Immunol Rev 2010, 6:195-204.
215. Yuen E.Y., Liu W., Karatsoreos I.N., Ren Y., Feng J., McEwen B.S., et al. Mechanisms for acute stress-induced enhancement of glutamatergic transmission and working memory. Mol Psychiat 2010, 16:156-170.
216. Shors T.J. Stressful experience and learning across the lifespan. Annu Rev Psychol 2006, 57:55-85.
217. Maggio N., Segal M. Corticosteroid regulation of synaptic plasticity in the hippocampus. Sci World J 2010, 10:462-469.
218. Avital A., Segal M., Richter-Levin G. Contrasting roles of corticosteroid receptors in hippocampal plasticity. J Neurosci: Official J Soc Neurosci 2006, 26:9130-9134.
219. Moghaddam B., Bolinao M.L., Stein-Behrens B., Sapolsky R. Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Brain Res 1994, 655:251-254.
220. Moghaddam B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J Neurochem 1993, 60:1650-1657.
221. Timmerman W., Cisci G., Nap A., De Vries J.B., Westerink B.H. Effects of handling on extracellular levels of glutamate and other amino acids in various areas of the brain measured by microdialysis. Brain Res 1999, 833:150-160.
222. Lowy M.T., Wittenberg L., Yamamoto B.K. Effect of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and aged rats. J Neurochem 1995, 65:268-274.
223. Bagley J., Moghaddam B. Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam. Neuroscience 1997, 77:65-73.
224. Ritchie L.J., De Butte M., Pappas B.A. Chronic mild stress exacerbates the effects of permanent bilateral common carotid artery occlusion on CA1 neurons. Brain Res 2004, 1014:228-235.
225. Xiao L., Feng C., Chen Y. Glucocorticoid rapidly enhances NMDA-evoked neurotoxicity by attenuating the NR2A-containing NMDA receptor-mediated ERK1/2 activation. Mol Endocrinol (Baltimore, Md.) 2010, 24:497-510.
226. Takahashi T., Kimoto T., Tanabe N. T.-aki Hattori, N. Yasumatsu, S. Kawato, Corticosterone acutely prolonged N-methyl-d-aspartate receptor-mediated Ca2+ elevation in cultured rat hippocampal neurons. J Neurochem 2002, 83:1441-1451.
227. Armanini M.P., Hutchins C., Stein B.A., Sapolsky R.M. Glucocorticoid endangerment of hippocampal neurons is NMDA-receptor dependent. Brain Res 1990, 532:7-12.
228. Silva R., Mesquita A.R., Bessa J., Sousa J.C., Sotiropoulos I., Leão P., et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta. Neuroscience 2008, 152:656-669.
229. Hasler G., Van der Veen J.W., Grillon C., Drevets W.C., Shen J. Effect of acute psychological stress on prefrontal GABA concentration determined by proton magnetic resonance spectroscopy. Am J Psychiat 2010, 167:1226-1231.
230. López J.F., Chalmers D.T., Little K.Y., Watson S.J., Bennett A.E. Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiat 1998, 43:547-573.
231. Alexander J.K., DeVries A.C., Kigerl K.A., Dahlman J.M., Popovich P.G. Stress exacerbates neuropathic pain via glucocorticoid and NMDA receptor activation. Brain Behav Immun 2009, 23:851-860.
232. Rosanoff A. Rising Ca:Mg intake ratio from food in USA Adults: a concern?. Magnesium Res: Official Organ Int Soc Develop Res Magnesium 2011.
233. Ford E.S., Mokdad A.H. Dietary magnesium intake in a national sample of US adults. J Nutrition 2003, 133:2879-2882.
234. Laires M.J., Monteiro C.P., Bicho M. Role of cellular magnesium in health and human disease. Frontiers Biosci 2004.
235. Saris N.E., Mervaala E., Karppanen H., Khawaja J.A., Lewenstam A. Magnesium, an update on physiological, clinical and analytical aspects. Clin Chim Acta; Int J Clin Chem 2000, 294:1-26.
236. Grimaldi B.L. The central role of magnesium deficiency in Tourette's syndrome: causal relationships between magnesium deficiency, altered biochemical pathways and symptoms relating to Tourette's syndrome and several reported comorbid conditions. Med Hypotheses 2002, 58:47-60.
237. Szewczyk B., Poleszak E., Sowa-Kućma M., Siwek M., Dudek D., Ryszewska-Pokraśniewicz B., et al. Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacol Rep: PR 2008, 60:588-589.
238. Vural H., Demirin H., Kara Y., Eren I., Delibas N. Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J Trace Elem Med Biol: Organ Soc Miner Trace Elem (GMS) 2010, 24:169-173.
239. Killilea D.W., Maier J.A.M. A connection between magnesium deficiency and aging: new insights from cellular studies. Magnesium Res: Official Organ Int Soc Develop Res Magnesium 2008, 21:77-82.
240. Spasov A.A., Iezhitsa I.N., Kharitonova M.V., Kravchenko M.S. Effect of magnesium chloride and magnesium l-aspartate on seizure threshold in rats under conditions of dietary magnesium deficiency. Bull Exp Biol Med 2007, 144:214-216.
241. Voss L.J., Sleigh J.W. Stability of brain neocortical slice seizure-like activity during low-magnesium exposure: measurement and effect of artificial cerebrospinal fluid temperature. J Neurosci Methods 2010, 192:214-218.
242. Maurois P., Pages N., Bac P., German-Fattal M., Agnani G., Delplanque B., et al. Threshold to N-methyl-d-aspartate-induced seizures in mice undergoing chronic nutritional magnesium deprivation is lowered in a way partly responsive to acute magnesium and antioxidant administrations. Br J Nutrition 2009, 101:317-321.
243. Cardoso C.C., Lobato K.R., Binfaré R.W., Ferreira P.K., Rosa A.O., Santos A.R.S., et al. Evidence for the involvement of the monoaminergic system in the antidepressant-like effect of magnesium. Prog Neuropsychopharmacol Biol Psychiat 2009, 33:235-242.
244. Eby G.A., Eby K.L. Magnesium for treatment-resistant depression: a review and hypothesis. Med Hypotheses 2010, 74:649-660.
245. Ozturk S., Cillier A.E. Magnesium supplementation in the treatment of dementia patients. Med Hypotheses 2006, 67:1223-1225.
246. Slutsky I., Abumaria N., Wu L.-J., Huang C., Zhang L., Li B., et al. Enhancement of learning and memory by elevating brain magnesium. Neuron 2010, 65:165-177.
247. Kampa B.M., Clements J., Jonas P., Stuart G.J. Kinetics of Mg2+ unblock of NMDA receptors: implications for spike-timing dependent synaptic plasticity. J Physiol 2004, 556:337-345.
248. Cavara N.A., Orth A., Hicking G., Seebohm G., Hollmann M. Residues at the tip of the pore loop of NR3B-containing NMDA receptors determine Ca2+ permeability and Mg2+ block. BMC Neurosci 2010, 11:133.
249. Qian A., Buller A.L., Johnson J.W. NR2 subunit-dependence of NMDA receptor channel block by external Mg2+. J Physiol 2005, 562:319-331.
250. Wang L.Y., MacDonald J.F. Modulation by magnesium of the affinity of NMDA receptors for glycine in murine hippocampal neurones. J Physiol 1995, 486(Pt 1):83-95.
251. Hashemzadeh-Gargari H., Guilarte T.R. Divalent cations modulate N-methyl-d-aspartate receptor function at the glycine site. J Pharmacol Exp Therapeut 1999, 290:1356-1362.
252. Nahum-Levy R., Tam E., Shavit S., Benveniste M. Glutamate but not glycine agonist affinity for NMDA receptors is influenced by small cations. J Neurosci: Official J Soc Neurosci 2002, 22:2550-2560.
253. Baumgart F., Rodríguez-Crespo I. D-amino acids in the brain: the biochemistry of brain serine racemase. FEBS J 2008, 275:3538-3545.
254. De Miranda J., Panizzutti R., Foltyn V.N., Wolosker H. Cofactors of serine racemase that physiologically stimulate the synthesis of the N-methyl-d-aspartate (NMDA) receptor coagonist d-serine. Proc Natl Acad Sci USA 2002, 99:14542-14547.
255. Kloda A., Clements J.D., Lewis R.J., Adams D.J. Adenosine triphosphate acts as both a competitive antagonist and a positive allosteric modulator at recombinant N-methyl-D-aspartate receptors. Mol Pharmacol 2004, 65:1386-1396.
256. Cevette M.J., Vormann J., Franz K. Magnesium and hearing. J Am Acad Audiol 2003, 14:202-212.
257. Regan R.F., Guo Y. Magnesium deprivation decreases cellular reduced glutathione and causes oxidative neuronal death in murine cortical cultures. Brain Res 2001, 890:177-183.
258. Begon S., Pickering G., Eschalier A., Mazur A., Rayssiguier Y., Dubray C. Role of spinal NMDA receptors, protein kinase C and nitric oxide synthase in the hyperalgesia induced by magnesium deficiency in rats. Br J Pharmacol 2001, 134:1227-1236.
259. Bardgett M.E., Schultheis P.J., McGill D.L., Richmond R.E., Wagge J.R. Magnesium deficiency impairs fear conditioning in mice. Brain Res 2005, 1038:100-106.
260. Bardgett M.E., Schultheis P.J., Muzny A., Riddle M.D., Wagge J.R. Magnesium deficiency reduces fear-induced conditional lick suppression in mice. Magnesium Res: Official Organ Int Soc Devel Res Magnesium 2007, 20:58-65.
261. Spasov A.A., Iezhitsa I.N., Kravchenko M.S., Kharitonova M.V. Features of central neurotransmission in animals in conditions of dietary magnesium deficiency and after its correction. Neurosci Behav Physiol 2009, 39:645-653.
262. Poleszak E. Modulation of antidepressant-like activity of magnesium by serotonergic system. J Neural Transmission (Vienna, Austria: 1996) 2007, 114:1129-1134.
263. Poleszak E. Benzodiazepine/GABA(A) receptors are involved in magnesium-induced anxiolytic-like behavior in mice. Pharmacol Rep: PR 2008, 60:483-489.
264. Darrow E., Strahlendorf J.C., Strahlendorf H.K. Extracellular magnesium concentration alters Purkinje cell responsiveness to serotonin and analogues. Eur J Pharmacol 1991, 209:19-25.
265. Murck H., Steiger A. Mg2+ reduces ACTH secretion and enhances spindle power without changing delta power during sleep in men-possible therapeutic implications. Psychopharmacology 1998, 137:247-252.
266. Held K., Antonijevic I.A., Künzel H., Uhr M., Wetter T.C., Golly I.C., et al. Oral Mg(2+) supplementation reverses age-related neuroendocrine and sleep EEG changes in humans. Pharmacopsychiatry 2002, 35:135-143.
267. Golf S.W., Bender S., Grüttner J. On the significance of magnesium in extreme physical stress. Cardiovasc Drugs Therapy/Sponsored Int Soc Cardiovasc Pharmacotherapy 1998, 12(Suppl. 2):197-202.
268. Billyard A.J., Eggett D.L., Franz K.B. Dietary magnesium deficiency decreases plasma melatonin in rats. Magnesium Res: Official Organ Int Soc Develop Res Magnesium. 2006, 19:157-161.
269. Jang S.-W., Liu X., Pradoldej S., Tosini G., Chang Q., Iuvone P.M., et al. N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc Natl Acad Sci USA 2010, 107:3876-3881.
270. Stanger O., Fowler B., Piertzik K., Huemer M., Haschke-Becher E., Semmler A., et al. Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations. Expert Rev Neurotherapeut 2009, 9:1393-1412.
271. Werder S.F. Cobalamin deficiency, hyperhomocysteinemia, and dementia. Neuropsychiat Disease Treatment 2010, 6:159-195.
272. Coppedè F. One-carbon metabolism and Alzheimer's disease: focus on epigenetics. Curr Genomics 2010, 11:246-260.
273. Kolínová M., Dvoráková J., Hladíková E., Preiss J., Hyánek J. Moderate hyperhomocysteinemia in patients treated for epilepsy. Prague Med Rep 2006, 107:227-241.
274. Purohit V., Abdelmalek M.F., Barve S., Benevenga N.J., Halsted C.H., Kaplowitz N., et al. Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutrition 2007, 86:14-24.
275. Tang B., Mustafa A., Gupta S., Melnyk S., James S.J., Kruger W.D. Methionine-deficient diet induces post-transcriptional downregulation of cystathionine beta-synthase. Nutrition (Burbank, Los Angeles County, CA) 2009, 26:1170-1175.
276. Konyenburg R, Nathen N. Treatment study of methylation cycle support in patients with chronic fatigue syndrome and fibromyalgia, 2009.
277. James S.J., Melnyk S., Fuchs G., Reid T., Jernigan S., Pavliv O., et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutrition 2009, 89:425-430.
278. Karakuła H., Opolska A., Kowal A., Domański M., Płotka A., Perzyński J. Does diet affect our mood? The significance of folic acid and homocysteine. Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 2009, 26:136-141.
279. Bottiglieri T., Laundy M., Crellin R., Toone B.K., Carney M.W., Reynolds E.H. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiat 2000, 69:228-232.
280. Folstein M., Liu T., Peter I., Buell J., Buel J., Arsenault L., et al. The homocysteine hypothesis of depression. Am J Psychiat 2007, 164:861-867.
281. Levine J., Timinsky I., Vishne T., Dwolatzky T., Roitman S., Kaplan Z., et al. Elevated serum homocysteine levels in male patients with PTSD. Depression Anxiety 2008, 25:E154-E157.
282. Nelson J.C. S-adenosyl methionine (SAMe) augmentation in major depressive disorder. Am J Psychiat 2010, 167:889-891.
283. Scott T.M., Tucker K.L., Bhadelia A., Benjamin B., Patz S., Bhadelia R., et al. Homocysteine and B vitamins relate to brain volume and white-matter changes in geriatric patients with psychiatric disorders. Am J Geriatr Psychiat: Official J Am Assoc Geriatr Psychiat 2004, 12:631-638.
284. Iosifescu D.V., Papakostas G.I., Lyoo I.K., Lee H.K., Renshaw P.F., Alpert J.E., et al. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I). Psychiat Res 2005, 140:291-299.
285. Papakostas G.I., Iosifescu D.V., Renshaw P.F., Lyoo I.K., Lee H.K., Alpert J.E., et al. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). Psychiat Res 2005, 140:301-307.
286. Kita Y., Baba H., Maeshima H., Nakano Y., Suzuki T., Arai H. Serum amyloid beta protein in young and elderly depression: a pilot study. Psychogeriat: Official J Japan Psychogeriat Soc 2009, 9:180-185.
287. Vitvitsky V., Thomas M., Ghorpade A., Gendelman H.E., Banerjee R. A functional transsulfuration pathway in the brain links to glutathione homeostasis. J Biol Chem 2006, 281:35785-35793.
288. Lin H.-C., Hsieh H.-M., Chen Y.-H., Hu M.-L. S-Adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters. Neurotoxicology 2009, 30:622-627.
289. Fuso A., Seminara L., Cavallaro R.A., D'Anselmi F., Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 2005, 28:195-204.
290. Losada M.E., Rubio M.C. Acute effects of S-adenosyl-L-methionine on catecholaminergic central function. Eur J Pharmacol 1989, 163:353-356.
291. Otero-Losada M.E., Rubio M.C. Acute changes in 5-HT metabolism after S-adenosyl-L-methionine administration. Gen Pharmacol 1989, 20:403-406.
292. Fonlupt P., Barailler J., Roche M., Cronenberger L., Pacheco H. Effects of S-adenosylmethionine and S-adenosylhomocysteine on in vivo synthesis of noradrenaline and serotonin in different parts of the rat brain. Comptes Rendus Des Séances De l'Académie Des Sciences. Série D, Sciences Naturelles 1979, 288:283-286.
293. Fonlupt P., Roche M., Cronenberger L., Pacheco H. Action of S-adenosyl-L-homocysteine on the metabolism of dopamine, norepinephrine and serotonin in rat brain. Arch Int Pharmacodyn Thérapie 1979, 240:35-44.
294. Fonlupt P., Roche M., Cronenberger L., Pacheco H. Activation by S-adenosylhomocysteine of norepinephrine and serotonin in vitro uptake in synaptosomal preparations from rat brain. Experientia 1979, 35:1089-1090.
295. Matté C., Mussulini B.H.M., dos Santos T.M., Soares F.M.S., Simão F., Matté A., et al. Hyperhomocysteinemia reduces glutamate uptake in parietal cortex of rats. Int J Develop Neurosci: Official J Int Soc Develop Neurosci 2010, 28:183-187.
296. Tyagi N., Gillespie W., Vacek J.C., Sen U., Tyagi S.C., Lominadze D. Activation of GABA-A receptor ameliorates homocysteine-induced MMP-9 activation by ERK pathway. J Cell Physiol 2009, 220:257-266.
297. Hohsfield L.A., Humpel C. Homocysteine enhances transmigration of rat monocytes through a brain capillary endothelial cell monolayer via ICAM-1. Curr Neurovasc Res 2010, 7:192-200.
298. Matté C., Pereira L.O., Dos Santos T.M., Mackedanz V., Cunha A.A., Netto C.A., et al. Acute homocysteine administration impairs memory consolidation on inhibitory avoidance task and decreases hippocampal brain-derived neurotrophic factor immunocontent: prevention by folic acid treatment. Neuroscience 2009, 163:1039-1045.
299. Kronenberg G., Harms C., Sobol R.W., Cardozo-Pelaez F., Linhart H., Winter B., et al. Folate deficiency induces neurodegeneration and brain dysfunction in mice lacking uracil DNA glycosylase. J Neurosci: Official J Soc Neurosci 2008, 28:7219-7230.
300. Rabaneda L.G., Carrasco M., López-Toledano M.A., Murillo-Carretero M., Ruiz F.A., Estrada C., et al. Homocysteine inhibits proliferation of neuronal precursors in the mouse adult brain by impairing the basic fibroblast growth factor signaling cascade and reducing extracellular regulated kinase 1/2-dependent cyclin E expression. FASEB J: Official Publication Federation Am Soc Exp Biol 2008, 22:3823-3835.
301. Luchowska E., Luchowski P., Paczek R., Ziembowicz A., Kocki T., Turski W.A., et al. Dual effect ofDL-homocysteine andS-adenosylhomocysteine on brain synthesis of the glutamate receptor antagonist, kynurenic acid. J Neurosci Res 2005, 79:375-382.
302. Linnebank M., Lutz H., Jarre E., Vielhaber S., Noelker C., Struys E., et al. Binding of copper is a mechanism of homocysteine toxicity leading to COX deficiency and apoptosis in primary neurons, PC12 and SHSY-5Y cells. Neurobiol Disease 2006, 23:725-730.
303. Rasić-Marković A., Stanojlović O., Hrncić D., Krstić D., Colović M., Susić V., et al. The activity of erythrocyte and brain Na+/K+ and Mg2+-ATPases in rats subjected to acute homocysteine and homocysteine thiolactone administration. Mol Cell Biochem 2009, 327:39-45.
304. Maler J.M., Seifert W., Hüther G., Wiltfang J., Rüther E., Kornhuber J., et al. Homocysteine induces cell death of rat astrocytes in vitro. Neurosci Lett 2003, 347:85-88.
305. Flott-Rahmel B., Schürmann M., Schluff P., Fingerhut R., Musshoff U., Fowler B., et al. Homocysteic and homocysteine sulphinic acid exhibit excitotoxicity in organotypic cultures from rat brain. Eur J Pediatr 1998, 157(Suppl.):S112-S117.
306. Poddar R., Paul S. Homocysteine-NMDA receptor-mediated activation of extracellular signal-regulated kinase leads to neuronal cell death. J Neurochem 2009, 110:1095-1106.
307. Do K.Q., Benz B., Binns K.E., Eaton S.A., Salt T.E. Release of homocysteic acid from rat thalamus following stimulation of somatosensory afferents in vivo: feasibility of glial participation in synaptic transmission. Neuroscience 2004, 124:387-393.
308. Do K.Q., Benz B., Sorg O., Pellerin L., Magistretti P.J. Beta-Adrenergic stimulation promotes homocysteic acid release from astrocyte cultures: evidence for a role of astrocytes in the modulation of synaptic transmission. J Neurochem 1997, 68:2386-2394.
309. Gonzalez-Correa J.A., De La Cruz J.P., Martin-Aurioles E., Lopez-Egea M.A., Ortiz P., Sanchez de la Cuesta F. Effects of S-adenosyl-L-methionine on hepatic and renal oxidative stress in an experimental model of acute biliary obstruction in rats. Hepatology (Baltimore, Md.) 1997, 26:121-127.
310. Mesa M.L., Carrizosa R., Martínez-Honduvilla C., Benito M., Fabregat I. Changes in rat liver gene expression induced by thioacetamide: protective role of S-adenosyl-L-methionine by a glutathione-dependent mechanism. Hepatology (Baltimore, Md.) 1996, 23:600-606.
311. Cederbaum A.I. Hepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome P450 2E1-induced liver injury. World J Gastroenterol: WJG 2010, 16:1366-1376.
312. De La Cruz J.P., Pavía J., González-Correa J.A., Ortiz P., Sánchez de la Cuesta F. Effects of chronic administration of S-adenosyl-l-methionine on brain oxidative stress in rats. Naunyn Schmiedebergs Arch Pharmacol 2000, 361:47-52.
313. De La Cruz J.P., Villalobos M.A., Cuerda M.A., Guerrero A., González-Correa J.A., Sánchez De La Cuesta F. Effects of S-adenosyl-L-methionine on lipid peroxidation and glutathione levels in rat brain slices exposed to reoxygenation after oxygen-glucose deprivation. Neurosci Lett 2002, 318:103-107.
314. Cavallaro R.A., Fuso A., Nicolia V., Scarpa S. S-adenosylmethionine prevents oxidative stress and modulates glutathione metabolism in TgCRND8 mice fed a B-vitamin deficient diet. J Alzheimer's Disease: JAD 2010, 20:997-1002.
315. Tchantchou F., Graves M., Falcone D., Shea T.B. S-adenosylmethionine mediates glutathione efficacy by increasing glutathione S-transferase activity: implications for S-adenosyl methionine as a neuroprotective dietary supplement. J Alzheimer's Disease: JAD 2008, 14:323-328.
316. Tchantchou F., Graves M., Ortiz D., Chan A., Rogers E., Shea T.B. S-adenosyl methionine: a connection between nutritional and genetic risk factors for neurodegeneration in Alzheimer's disease. J Nutrition Health Aging 2006, 10:541-544.
317. Scalabrino G., Veber D., Mutti E. Experimental and clinical evidence of the role of cytokines and growth factors in the pathogenesis of acquired cobalamin-deficient leukoneuropathy. Brain Res Rev 2008, 59:42-54.
318. Scalabrino G. The multi-faceted basis of vitamin B12 (cobalamin) neurotrophism in adult central nervous system: Lessons learned from its deficiency. Prog Neurobiol 2009, 88:203-220.
319. Stellwagen D., Beattie E.C., Seo J.Y., Malenka R.C. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci: Official J Soc Neurosci 2005, 25:3219-3228.
320. Vesce S., Rossi D., Brambilla L., Volterra A. Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation 2007, Elsevier.
321. Maes M., Galecki P. Y.S. Chang 2010, M. Berk, A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness., Progress In Neuro-psychopharmacology & Biological Psychiatry.
322. Magalhães P.V., Dean O.M., Bush A.I., Copolov D.L., Malhi G.S., Kohlmann K., et al. N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J Affect Disorders 2010.
323. Dean O., Giorlando F., Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiat Neurosci, JPN 2010, 35:100057.
324. Avshalumov M.V., MacGregor D.G., Sehgal L.M., Rice M.E. The glial antioxidant network and neuronal ascorbate: protective yet permissive for H(2)O(2) signaling. Neuron Glia Biol 2004, 1:365-376.
325. Ballatori N., Krance S.M., Notenboom S., Shi S., Tieu K., Hammond C.L. Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 2009, 390:191-214.
326. Harrison F.E., May J.M. Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic Biol Med 2009, 46:719-730.
327. Bodhinathan K., Kumar A., Foster T.C. Intracellular redox state alters NMDA receptor response during aging through Ca2+/calmodulin-dependent protein kinase II. J Neurosci: Official J Soc Neurosci 2010, 30:1914-1924.
328. Kimura Y., Kimura H. Hydrogen sulfide protects neurons from oxidative stress. FASEB J: Official Publication Federation Am Soc Exp Biol 2004, 18:1165-1167.
329. Kuzkaya N., Weissmann N., Harrison D.G., Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 2003, 278:22546-22554.
330. Hopper R.A., Garthwaite J. Tonic and phasic nitric oxide signals in hippocampal long-term potentiation. J Neurosci: Official J Soc Neurosci 2006, 26:11513-11521.
331. Antoniades C., Shirodaria C., Warrick N., Cai S., de Bono J., Lee J., et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006, 114:1193-1201.
332. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiat 2009, 65:732-741.
333. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiat 2010.
334. Moncada S., Bolaños J.P. Nitric oxide. Cell bioenergetics and neurodegeneration., Journal Of Neurochemistry. 2006, 97:1676-1689.
335. Brown G.C., Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol 2003, 27:325-355.
336. Brown G.C. Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem Soc Trans 2007, 35:1119-1121.
337. Bal-Price A., Brown G.C. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci: Official J Soc Neurosci 2001, 21:6480-6491.
338. Harvey B.H., Oosthuizen F., Brand L., Wegener G., Stein D.J. Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus. Psychopharmacology 2004, 175:494-502.
339. Nair A., Bonneau R.H. Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J Neuroimmunol 2006, 171:72-85.
340. Mok M.H.S., Fricker A.-C., Weil A., Kew J.N.C. Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels. Neuropharmacology 2009, 57:242-249.
341. Ribeiro C.A.J., Grando V., Dutra Filho C.S., Wannmacher C.M.D., Wajner M. Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats. J Neurochem 2006, 99:1531-1542.
342. Braidy N., Grant R., Adams S., Brew B.J., Guillemin G.J. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotoxicity Res 2009, 16:77-86.
343. Sas K., Robotka H., Toldi J., Vécsei L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 2007, 257:221-239.
344. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 2008, 29:287-291.
345. Erhardt S., Schwieler L., Nilsson L., Linderholm K., Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol Behav 2007, 92:203-209.
346. Murrough J.W., Mao X., Collins K.A., Kelly C., Andrade G., Nestadt P., et al. Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: Comparison with major depressive disorder. NMR Biomed 2010, 23:643-650.
347. Mathew S.J., Mao X., Keegan K.A., Levine S.M., Smith E.L.P., Heier L.A., et al. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed 2009, 22:251-258.
348. Myhill S., Booth N.E., McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009, 2:1-16.
349. Rezin G.T., Amboni G., Zugno A.I., Quevedo J., Streck E.L. Mitochondrial dysfunction and psychiatric disorders. Neurochem Res 2009, 34:1021-1029.
350. Knott A.B., Perkins G., Schwarzenbacher R., Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci 2008, 9:505-518.
351. Burnstock G. Purinergic cotransmission. Exp Physiol 2009, 94:20-24.
352. Khakh B.S., Burnstock G. The double life of ATP. Sci Am 2009, 301:84-90. 92.
353. Novelli A., Reilly J.A., Lysko P.G., Henneberry R.C. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988, 451:205-212.
354. Won S.J., Kim D.Y., Gwag B.J. Cellular and molecular pathways of ischemic neuronal death. J Biochem Mol Biol 2002, 35:67-86.
355. Sheldon AL, Robinson MB. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int 51;n.d.:333-55.
356. Katsuki H., Watanabe Y., Fujimoto S., Kume T., Akaike A. Contribution of endogenous glycine and d-serine to excitotoxic and ischemic cell death in rat cerebrocortical slice cultures. Life Sci 2007, 81:740-749.
357. Ioudina M., Uemura E., Greenlee H.W. Glucose insufficiency alters neuronal viability and increases susceptibility to glutamate toxicity. Brain Res 2004, 1004:188-192.
358. Barth A., Nguyen L.B., Barth L., Newell D.W. Glycine-induced neurotoxicity in organotypic hippocampal slice cultures. Exp Brain Res - Experimentelle Hirnforschung. Expérimentation Cérébrale 2005, 161:351-357.
359. Porkka-Heiskanen T., Kalinchuk A.V. Adenosine, energy metabolism and sleep homeostasis. Sleep Med Rev 2010.
360. Wigren H.-K., Rytkönen K.-M., Porkka-Heiskanen T. Basal forebrain lactate release and promotion of cortical arousal during prolonged waking is attenuated in aging. J Neurosci: Official J Soc Neurosci 2009, 29:11698-11707.
361. Saransaari P., Oja S.S. Mechanisms of inhibitory amino acid release in the brain stem under normal and ischemic conditions. Neurochem Res 2010, 35:1948-1956.
362. Deckert J., Gleiter C.H. Adenosine - an endogenous neuroprotective metabolite and neuromodulator. J Neural Transm 1994, 43(Suppl.):23-31.